Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

November 25, 2015 7:30 PM ET


Company Overview of Edge Therapeutics, Inc.

Company Overview

Edge Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and commercializes hospital-based therapies for acute life-threatening neurological conditions. Its lead product candidate, EG-1962, a polymer-based microparticle used for the treatment of aneurysmal subarachnoid hemorrhage (cSDH). The company also develops other product candidates, which are in pre-clinical development stages, including EG-1964, to prevent recurrent bleeding after treatment for cSDH; and EG-1963, to prevent rebleeding following surgeries outside the brain. Edge Therapeutics, Inc. was founded in 2009 and is headquartered in Berkeley Heights, New Jersey.

200 Connell Drive

Suite 1600

Berkeley Heights, NJ 07922

United States

Founded in 2009

17 Employees





Key Executives for Edge Therapeutics, Inc.

Co-Founder, Chief Executive Officer, President and Director
Age: 50
Total Annual Compensation: $471.1K
Co-Founder, Chief Scientific Officer and Director
Age: 53
Total Annual Compensation: $353.4K
Chief Financial Officer
Age: 55
Total Annual Compensation: $284.6K
Chief Accounting and Operations Officer
Age: 63
Total Annual Compensation: $278.4K
Chief Medical Officer
Age: 62
Total Annual Compensation: $359.8K
Compensation as of Fiscal Year 2014.

Edge Therapeutics, Inc. Key Developments

Edge Therapeutics, Inc. Announces Unaudited Earnings Results for the Third Quarter and Nine Months Ended September 30, 2015

Edge Therapeutics, Inc. announced unaudited earnings results for the third quarter and nine months ended September 30, 2015. For the quarter, the company reported loss from operations of $8,484,860 against $3,560,349 a year ago. Loss before income taxes was $10,130,050 against $3,518,133 a year ago. Net loss was $10,130,050 against $3,518,133 a year ago. Net loss attributable to common stockholders was $11,957,618 against $3,882,799 a year ago. Loss per share attributable to common stockholders basic and diluted was $7.08 against $2.30 a year ago. For the nine months, the company reported loss from operations of $17,627,438 against $9,176,825 year ago. Loss before income taxes was $20,119,498 against $9,038,388 a year ago. Net loss was $20,119,498 against $9,038,388 a year ago. Net loss attributable to common stockholders was $24,376,581 against $10,120,495 a year ago. Loss per share attributable to common stockholders basic and diluted was $14.44 against $5.99 a year ago.

Edge Therapeutics, Inc. Appoints W. Bradford Middlekauff as Senior Vice President, General Counsel and Secretary

Edge Therapeutics, Inc. announced that W. Bradford Middlekauff has joined as Senior Vice President, General Counsel and Secretary, reporting to Brian A. Leuthner, President and Chief Executive Officer. Most recently, Mr. Middlekauff served as Executive in Residence at Princeton University and as Chief Business Officer and General Counsel for Transparency Life Sciences, LLC.

Edge Therapeutics Receives European Commission Orphan Drug Designation for EG-1962 in the Treatment of Patients with Subarachnoid Hemorrhage

Edge Therapeutics, Inc. announced that the European Commission (EC) has granted orphan drug designation to EG-1962, its lead product candidate, which is in development for treating patients that have suffered an aneurysmal subarachnoid hemorrhage (aSAH), also known as a ruptured brain aneurysm. The designation follows a positive opinion from the European Medicine Agency (EMA) Committee for Orphan Medicinal Products (COMP). Orphan drug designation by the European Commission provides regulatory and financial incentives for companies to develop and market therapies that treat a life-threatening or chronically debilitating condition affecting no more than five in 10,000 persons in the European Union (EU), and where no satisfactory treatment is currently available. In addition to a 10-year period of marketing exclusivity in the EU following product approval, receiving orphan drug designation provides incentives for companies seeking protocol assistance from the EMA during the product development phase, and direct access to the centralized authorization procedure.

Similar Private Companies By Industry

Company Name Region
DeuteRx, LLC United States
Sanofi Pasteur VaxDesign Corporation United States
Apsara Therapeutics United States
Polymerix Corporation United States
Arbor Vita Corporation United States

Recent Private Companies Transactions

Private Placement
April 6, 2015
Private Placement
December 31, 2014

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Edge Therapeutics, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at